Suprachoroidal injection in the treatment of diabetic macular edema: mechanisms, clinical advances, and future perspectives

Diabetic macular edema (DME) is the leading cause of vision loss in patients with diabetes. Conventional therapies like intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids are often limited by the frequent injections and risks of complications. Suprachoroidal space (SCS) injection has emerged as a novel drug delivery technique. It targets eye precisely, resulting in high drug concentration in the posterior segment while reducing exposure to